Merck’s Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is FDA-approved for subcutaneous use in adults across 38 solid tumor indications already cleared for intravenous (IV) Keytruda (pembrolizumab). This includes melanoma, lung, bladder and head and neck cancers. The therapy is the first immune checkpoint inhibitor (a type of immunotherapy that helps the immune system detect and […]